Use of amyloid-PET to determine cutpoints for CSF markers

Neurology

Volumn 86, Issue 1, 2016, Pages 50-58

  Zwan, Marissa D ^a   Rinne, Juha O ^b   Hasselbalch, Steen G ^c   Nordberg, Agneta ^d,e   Lleó, Alberto ^f,g   Herukka, Sanna Kaisa ^h   Soininen, Hilkka ^h   Law, Ian ^c   Bahl, Justyna M C ^h,i   Carter, Stephen F ^d,j   Fortea, Juan ^f,g   Blesa, Rafael ^f,g   Teunissen, Charlotte E ^a   Bouwman, Femke H ^a   Van Berckel, Bart N M ^a   Visser, Pieter J ^a,k  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TURKU   (Finland)

^c International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^d KAROLINSKA INSTITUTE   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

ⁱ STATENS SERUM INSTITUT   (Denmark)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k MAASTRICHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; PITTSBURGH COMPOUND B; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; COMPARATIVE STUDY; DEMENTIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; AMYLOID PLAQUE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; MIDDLE AGED; UTILIZATION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITIVE DYSFUNCTION; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY;

EID: 84952360236     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002081     Document Type: Article

References (40)

1. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimers disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216
2. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimers disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-367
3. Blennow K, Dubois B, Fagan AM, Lewczuk P, De Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimers disease. Alzheimers Dement 2015; 11: 58-69
4. Vos SJ, Visser PJ, Verhey F, et al. Variability of CSF Alzheimers disease biomarkers: implications for clinical practice. PLoS One 2014; 9: e100784
5. Mattsson N, Andreasson U, Persson S, et al. CSF biomarker variability in the Alzheimers Association quality control program. Alzheimers Dement 2013; 9: 251-261
6. Mulder C, Verwey NA, van Der Flier WM, et al. Amyloidbeta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010; 56: 248-253
7. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005; 64: 1294-1297
8. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimers disease. Neurosci Lett 2003; 352: 67-69
9. Alcolea D, Martinez-Lage P, Izagirre A, et al. Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimers disease: a multicenter study in Spain. J Alzheimers Dis 2014; 39: 719-726
10. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of betaamyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol 2008; 65: 1304-1309
11. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimers disease. Brain 2008; 131: 1630-1645
12. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015; 313: 1939-1949
13. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 2015; 313: 1924-1938
14. Zwan M, van HA, Ossenkoppele R, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB pet in a memory clinic cohort. J Alzheimers Dis 2014; 41: 801-807
15. Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A. Concordance and diagnostic accuracy of [11C]PIB PET and cerebrospinal fluid biomarkers in a sample of patients with mild cognitive impairment and Alzheimers disease. J Alzheimers Dis 2015; 45: 1077-1088
16. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 2011; 7: 263-269
17. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimers disease: revising the NINCDSADRDA criteria. Lancet Neurol 2007; 6: 734-746
18. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554
19. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260
20. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872
21. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54(suppl 5): S15-S19
22. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDSSPSP international workshop. Neurology 1996; 47: 1-9
23. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, Dekosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142
24. Ossenkoppele R, Tolboom N, Foster-Dingley JC, et al. Longitudinal imaging of Alzheimer pathology using [11C] PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging 2012; 39: 990-1000
25. Frederiksen KS, Hasselbalch SG, Hejl AM, Law I, Hojgaard L, Waldemar G. Added diagnostic value of (11)C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra 2012; 2: 610-621
26. Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009; 73: 1186-1192
27. Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282-1289
28. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519
29. Tolboom N, van Der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18FFDDNP binding. J Nucl Med 2009; 50: 1464-1470
30. Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimers disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009; 65: 927-934
31. Koivunen J, Pirttila T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid betaamyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 26: 378-383
32. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29: 1456-1465
33. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of b-amyloid. Ann Neurol 2013; 74: 826-836
34. Ances BM, Christensen JJ, Teshome M, et al. Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB: a case-control study. Neurology 2010; 75: 111-115
35. Scholl M, Wall A, Thordardottir S, et al. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012; 79: 229-236
36. Mattsson N, Insel PS, Donohue M, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimers disease. Brain 2015; 138: 772-783
37. Duits FH, Teunissen CE, Bouwman FH, et al. The cerebrospinal fluid Alzheimer profile: easily said, but what does it mean? Alzheimers Dement 2014; 10: 713-723.e2
38. Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimers disease. Eur J Nucl Med Mol Imaging 2012; 39: 983-989
39. Vandenberghe R, Van Laere K, Ivanoiu A, et al. 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319-329
40. Zetterberg H, Visser PJ. Fluid biomarkers for Alzheimers disease: standardization and recent developments. Biomark Med 2012; 6: 363-364